RHYS committed to growing globally as a R&D driven company. We have a leading portfolio of medicines that prevent, treat and cure diseases across a broad range of therapeutic areas, and an industry-leading pipeline of promising new products in areas such as oncology, cardiovascular disease and diabetes demonstrates our commitment to pursue products and diseases where we can offer significant contributions.

RHYS is committed to develop innovative products through novel drug delivery systems to provide safe, effective, and convenient delivery of small molecules, peptides and complex proteins.

To ensure that we deliver the value our patients and customers need, we are focused on continually improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions.